FDA Grants Fast Track Designation to MorphoSys AG’s Promising Endometrial Cancer Treatment
MorphoSys AG today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for tulmimetostat, an innovative dual inhibitor targeting EZH2 and EZH1. This breakthro ...